MicroRNA‑373 promotes cell migration via targeting salt‑inducible kinase 1 expression in melanoma

Bai,Xinping; Yang,Ming; Xu,Yi

doi:10.3892/etm.2018.6784

MicroRNA‑373 promotes cell migration via targeting salt‑inducible kinase 1 expression in melanoma

Authors:
- Xinping Bai
- Ming Yang
- Yi Xu
View Affiliations

Affiliations: Department of Plastic Surgery, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Department of Plastic Surgery, The Third People's Hospital of Hubei Province, Wuhan, Hubei 430033, P.R. China
Published online on: September 21, 2018 https://doi.org/10.3892/etm.2018.6784
Pages: 4759-4764

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is well established that altered expression of microRNAs (miRs) is critical in numerous human cancer types. Nevertheless, the molecular mechanisms of many miRs are yet to be elucidated. In the present study, reverse transcription‑quantitative polymerase chain reaction and western blot analyses, and cell migration assays were performed to verify dysregulation of miR‑373 in melanoma and its biological function. The transcriptional level of miR‑373 was identified to be upregulated in melanoma tissues and cell lines compared with nevus and normal melanocytes. miR‑373 was identified to function as an oncomiR, promoting melanoma cell migration. Notably, miR‑373 was observed to suppress its downstream gene salt‑inducible kinase 1 (SIK1) through directly binding the 3'‑untranslated region of SIK1 expression. Furthermore, reduced SIK1 expression was identified to be responsible for the oncogenic effect of miR‑373. In conclusion, the present study indicates that miR‑373 functions as an oncomiR to promote melanoma progression through targeting SIK1 expression. This may provide a new therapeutic approach for melanoma.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cellerino P, Corsi F, Morandi E, Foschi D and Trabucchi E: Metastatic melanoma of the gallbladder. Eur J Surg Oncol. 26:815–816. 2000. View Article : Google Scholar : PubMed/NCBI
3	Haskaraca MF, Ozsoy M, Ozsan I and Kurt K: Primary malignant melanoma of the gallbladder: A case report and review of the literature. Case Rep Surg. 2012:6935472012.PubMed/NCBI
4	Corrie P, Hategan M, Fife K and Parkinson C: Management of melanoma. Br Med Bull. 111:149–162. 2014. View Article : Google Scholar : PubMed/NCBI
5	Burki TK: Defining the genetics of melanoma progression. Lancet Oncol. 17:e72016. View Article : Google Scholar : PubMed/NCBI
6	Zeng Y and Cullen BR: Sequence requirements for micro RNA processing and function in human cells. Rna. 9:112–123. 2003. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
8	Li YC, Li CF, Chen LB, Li DD, Yang L, Jin JP and Zhang B: MicroRNA-766 targeting regulation of SOX6 expression promoted cell proliferation of human colorectal cancer. Onco Targets Ther. 8:2981–2988. 2015. View Article : Google Scholar : PubMed/NCBI
9	Cao J, Liu J, Xu R, Zhu X, Liu L and Zhao X: MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. Mol Med Rep. 13:75–82. 2016. View Article : Google Scholar : PubMed/NCBI
10	Puglisi F, Minisini AM, De Angelis C and Arpino G: Overcoming treatment resistance in HER2-positive breast cancer: Potential strategies. Drugs. 72:1175–1193. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bennett PE, Bemis L, Norris DA and Shellman YG: miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics. 45:1049–1059. 2013. View Article : Google Scholar : PubMed/NCBI
12	da Cruz AT and Jasiulionis MG: miRNAs and melanoma: How are they connected? Dermatol Res Pract. 2012:5283452012.PubMed/NCBI
13	Mannavola F, Tucci M, Felici C, Stucci S and Silvestris F: miRNAs in melanoma: A defined role in tumor progression and metastasis. Expert Rev Clin Immunol. 12:79–89. 2016. View Article : Google Scholar : PubMed/NCBI
14	Mueller DW, Rehli M and Bosserhoff AK: miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 129:1740–1751. 2009. View Article : Google Scholar : PubMed/NCBI
15	Bertorello AM and Zhu JK: SIK1/SOS2 networks: Decoding sodium signals via calcium-responsive protein kinase pathways. Pflugers Arch. 458:613–619. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lee J, Tong T, Takemori H and Jefcoate C: Stimulation of StAR expression by cAMP is controlled by inhibition of highly inducible SIK1 via CRTC2, a co-activator of CREB. Mol Cell Endocrinol. 408:80–89. 2015. View Article : Google Scholar : PubMed/NCBI
17	Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, et al: SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal. 2:ra352009. View Article : Google Scholar : PubMed/NCBI
18	Yao YH, Cui Y, Qiu XN, Zhang LZ, Zhang W, Li H and Yu JM: Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non-small cell lung cancer cells. Chin J Cancer. 35:502016. View Article : Google Scholar : PubMed/NCBI
19	Selvik LK, Rao S, Steigedal TS, Haltbakk I, Misund K, Bruland T, Prestvik WS, Lægreid A and Thommesen L: Salt-inducible kinase 1 (SIK1) is induced by gastrin and inhibits migration of gastric adenocarcinoma cells. PLoS One. 9:e1124852014. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Zhai W, Sun Y, Jiang M, Wang M, Gasiewicz TA, Zheng J and Chang C: Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia. Oncogene. 35:4866–4880. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wei F, Cao C, Xu X and Wang J: Diverse functions of miR-373 in cancer. J Transl Med. 13:1622015. View Article : Google Scholar : PubMed/NCBI
23	Wei F, Wang Q, Su Q, Huang H, Luan J, Xu X and Wang J: miR-373 inhibits glioma cell U251 migration and invasion by down-regulating CD44 and TGFBR2. Cell Mol Neurobiol. 36:1389–1397. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL and Zhang S: MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget. 5:12291–12303. 2014.PubMed/NCBI
25	Eyking A, Reis H, Frank M, Gerken G, Schmid KW and Cario E: MiR-205 and MiR-373 are associated with aggressive human mucinous colorectal cancer. PLoS One. 11:e01568712016. View Article : Google Scholar : PubMed/NCBI
26	Ding W, Fan XL, Xu X, Huang JZ, Xu SH, Geng Q, Li R, Chen D and Yan GR: Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer. PLoS One. 10:e01351282015. View Article : Google Scholar : PubMed/NCBI
27	Chen D, Dang BL, Huang JZ, Chen M, Wu D, Xu ML, Li R and Yan GR: MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer. Oncotarget. 6:32701–32712. 2015.PubMed/NCBI
28	Qu C, He D, Lu X, Dong L, Zhu Y, Zhao Q, Jiang X, Chang P, Jiang X, Wang L, et al: Salt-inducible kinase (SIK1) regulates HCC progression and WNT/β-catenin activation. J Hepatol. 64:1076–1089. 2016. View Article : Google Scholar : PubMed/NCBI
29	Ren ZG, Dong SX, Han P and Qi J: miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer. Oncol Rep. 35:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI
30	Chen JL, Chen F, Zhang TT and Liu NF: Suppression of SIK1 by miR-141 in human ovarian cancer cell lines and tissues. Int J Mol Med. 37:1601–1610. 2016. View Article : Google Scholar : PubMed/NCBI